Skip to main content Skip to main navigation menu Skip to site footer

The clinicopathological characteristics of borderline ovarian tumors at Dr. Soetomo Hospital, Surabaya: a single center study

  • Setyo Teguh Waluyo ,
  • Brahmana Askandar Tjokroprawiro ,


Background: Borderline ovarian tumors (BOT) are a subset of epithelial neoplasms histologically defined as atypical epithelial proliferation without stromal invasion. BOTs account for 10-20% of ovarian cancer cases. This study aims to know the clinical and pathological characteristics and determine the differences in these characteristics based on age classification.

Methods: A 5-year retrospective study was conducted in a single center. Information was obtained from the pathological reports of 53 patients with BOTs between 2016-2021. Statistical analysis was performed using the Student’s t-test with SPSS version 20.0 (SPSS Inc). Continuous data were analyzed using t-tests, and categorical data were tested with Chi-square or Fisher's exact test to assess differences in clinical and pathological features between the <40 years and the >40 years age groups

Results: Most of the tumor diameters were >10 cm (92.45%) and <10 cm (7.55%). For histopathological description, respectively are MBOT (69.81%), SBOT (24.53%), EBOT (3.77%), and SMBOT (1.89%). There were 29 (45.28%) cases with elevated CA125 levels, and normal levels were 24 (45.283%). Unilateral tumors were 36 (67.92%), and bilateral tumors were 17 cases (32.08%). Serous borderline Ovarian tumor histology was higher in the >40 years group than in the < 40 years group (p<0.05). There was no relationship between cancer antigen (CA) 125 levels and bilaterality, tumor size, or stage (p > 0.05). The mean CA 125 level was higher in the >40 years group (257.92± 64.35) than in the <40 years group (74.42±63.02) (p < 0.05).

Conclusion: The median age of BOT was 40 years old and the majority had a large unilateral tumor with mucinous, the most common histologic type. There was a correlation between age, SBOT histologic type, and elevated CA-125.


  1. Schüler S, Ponnath M, Engel J, Ortmann O. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet. 2013;287(6):1187–1204.
  2. Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, et al. Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls. Cancer Prev Res. 2013;6(8):811–821.
  3. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–394.
  4. Chen J, Chang C, Huang HC, Chung YC, Huang HJ, Liou WS, et al. Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model. Taiwan J Obstet Gynecol. 2015 A;54(4):398–402.
  5. Alves AS, Félix A, Cunha TM. Clues to the diagnosis of borderline ovarian tumours: An imaging guide. Eur J Radiol. 2021;143:109904.
  6. McCluggage WG. Ovarian borderline tumours: a review with comparison of serous and mucinous types. Diagnostic Histopathol. 2014;20(9):333–350.
  7. Kumari S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population. Gynecol Oncol Reports. 2021;36:100756.
  8. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, et al. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol. 2011;120(3):480–4.
  9. Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, et al. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol. 2015;136(3):491–497.
  10. Anggorowati N, Kurniasari CR, Damayanti K, Cahyanti T, Widodo I, Ghozali A, et al. Histochemical and Immunohistochemical Study of α-SMA, Collagen, and PCNA in Epithelial Ovarian Neoplasm. Asian Pac J Cancer Prev. 2017;18(3):667–671.
  11. Fang C, Zhao L, Chen X, Yu A, Xia L, Zhang P. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors. BMC Cancer. 2018;18(1):1–11.
  12. Hashmi AA, Hussain ZF, Bhagwani AR, Edhi MM, Faridi N, Hussain SD, et al. Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors: an institutional perspective. BMC Res Notes. 2016;9(1):1-4.
  13. Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol. 2012;126(1):157–166.
  14. Niu L, Tian H, Xu Y, Cao J, Zhang X, Zhang J, et al. Recurrence characteristics and clinicopathological results of borderline ovarian tumors. BMC Womens Health. 2021;21(1):1–7.
  15. Park S Bin, Kim MJ, Lee KH, Ko Y. Ovarian serous surface papillary borderline tumor: characteristic imaging features with clinicopathological correlation. Br J Radiol. 2018;91:1088.
  16. Guvenal T, Dursun P, Hasdemir PS, Hanhan M, Guven S, Yetimalar H, et al. Effect of surgical staging on 539 patients with borderline ovarian tumors: A Turkish Gynecologic Oncology Group study. Gynecol Oncol. 2013;131(3):546–550.
  17. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of Borderline Tumors With Particular Interest to Persistence, Recurrence, and Progression to Invasive Carcinoma: A Prospective Study. J Clin Oncol. 2001;19(10):2658–2664.
  18. du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors. Ann Oncol. 2016;27:i20–2.
  19. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011;205(2):103–110.
  20. Huchon C, Bourdel N, Abdel Wahab C, Azaïs H, Bendifallah S, Bolze PA, et al. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers. J Gynecol Obstet Hum Reprod. 2021;50(1):101965.
  21. Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol. 2014;25(7):1320–1327.
  22. Sobiczewski P, Piatek S, Michalski W, Kupryjańczyk J, Maciejewski T, Ołtarzewski M, et al. Obstetric outcomes after conservative management of ovarian borderline tumors in women of reproductive age: A single center experience. Eur J Obstet Gynecol Reprod Biol. 2022;269:126–131.
  23. Trimble EL, Trimble CL. Ovarian tumors of low malignant potential. Curr Treat Options Oncol. 2001;2(2):103–108.
  24. Benito V, Lubrano A, Arencibia O, Medina N, Álvarez Eva E, Andújar M, et al. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol. 2010;153(2):188–192.
  25. Cybulska P, Paula ADC, Tseng J, Leitao Jr MM, Bashashati A, Huntsman DG, et al. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecol Oncol. 2019;154(3):516–523.
  26. Pierson WE, Peters PN, Chang MT, Chen L, Quigley DA, Ashworth A, et al. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020;157(1):55–61.
  27. Mulawardhana P, Hartono P, Nugroho H, Ayuningtyas A. Death of 43 Indonesian women with ovarian cancer: A case series. Int J Surg Case Rep. 2021;78:391–396.
  28. Prakosa T, Mudigdo A, Purwanto B, Wasita B, Cilmiaty R, Widianingsih V. A cross-sectional study: The correlation of pro-angiogenic factors expression level and epithelial ovarian cancer staging. Bali Medical Journal. 2020;9(1):125–128
  29. Prat J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017;41:15–30.
  30. Prat J. The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type. Ann Oncol. 2014;25(7):1255–1258.
  31. Soovares P, Pasanen A, Similä-Maarala J, Bützow R, Lassus H. Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade. Gynecol Oncol. 2022;164(1):187–194.
  32. Perbowo P, Askandar B. KLK6 as a Predictor of Ovarian Malignancy. Med Mod - Mod Med. 2019;26(4):189–195.
  33. Childress KJ, Patil NM, Muscal JA, Dietrich JE, Venkatramani R. Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review. J Pediatr Adolesc Gynecol. 2018;31(1):48–54.
  34. Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S. Symptoms and referral of women with epithelial ovarian tumors. Int J Gynecol Obstet. 2005;88(1):31–37.
  35. Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S, Fukatsu T, et al. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol. 1990;38(1):90–98.
  36. Wang D, Jia S, Jia C, Cao D, Yang J, Yang J, et al. Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study. Gynecol Oncol. 2022;165(3):446–452.
  37. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study. Ann Oncol. 1996;7(4):361–364.
  38. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104(5):863–870.
  39. Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868.

How to Cite

Setyo Teguh Waluyo, & Tjokroprawiro, B. A. (2023). The clinicopathological characteristics of borderline ovarian tumors at Dr. Soetomo Hospital, Surabaya: a single center study. Bali Medical Journal, 12(1), 615–620.




Search Panel

Setyo Teguh Waluyo
Google Scholar
BMJ Journal

Brahmana Askandar Tjokroprawiro
Google Scholar
BMJ Journal